MiNK Therapeutics annual return on equity
2022
MiNK Therapeutics Return on Equity (ROE) Growth & History (INKT)
MiNK Therapeutics's return on equity was −239.50% for fiscal 2022.
View full MiNK Therapeutics company overviewMiNK Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −239.50% | — |
MiNK Therapeutics quarterly return on equity
Q1.22
Q2.22
Q3.22
Q4.22
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2022 | 2022-12-31 | −244.53% | — |
| Q3 2022 | 2022-09-30 | −61.94% | — |
| Q2 2022 | 2022-06-30 | −39.44% | — |
| Q1 2022 | 2022-03-31 | −37.86% | — |
MiNK Therapeutics return on equity trends
The latest reported quarter, Q4 2022, shows −244.53%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MiNK Therapeutics source filings ↗